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ABSTRACT
In the present studies, we have established that RSV
can elicit a more pathogenic environment dependent
on improper DC-associated sensitization. Our initial
studies demonstrated that RSV, but not influenza, infec-
tion during an allergen exposure into the airway in-
duced a more severe allergen response. The RSV-in-
duced exacerbation included an increased Th2 cyto-
kine response and pathophysiology as monitored by
AHR and mucus overproduction. DCs played a central
role in the allergen-induced responses, as instilling
RSV-infected BMDC into the airway could recapitulate a
live virus challenge. With the use of CCR6/ mice that
have a primary defect in the recruitment of mDC sub-
sets, reduced exacerbation of disease was observed
when RSV was administered along with allergen. Fur-
thermore, sensitization of mice with RSV-infected
BMDC into the airway produced a more severe immune
response to a live virus challenge. Subsequently, using
RSV-infected BMDC from CCR7/ mice (that do not
migrate efficiently to LNs) to sensitize the exacerbated
response demonstrated that the response was depen-
dent on DC migration to the LN. Finally, the ability of
RSV-infected DCs to elicit an exacerbated, allergen-in-
duced pathogenic response could be maintained for as
long as 3 weeks, suggesting that RSV-infected DCs
themselves created an altered immune environment
that impacts off-target mucosal responses that could
have prolonged effects. J. Leukoc. Biol. 94: 5–15;
2013.
Introduction
The induction of immune responses in the host often deter-
mines the nature and the severity of the ensuing illness during
infectious diseases and may even dictate future local immune
responses. Studies have shown that patients with severe respira-
tory viral infections have an increased risk for the development
of chronic pulmonary diseases [1–5]. A number of respiratory
viruses have been implicated in the induction of pulmonary
diseases, including infections with RSV, rhinovirus, influenza,
parainfluenza, and adenovirus. How the interactions of spe-
cific viruses, underlying immune conditions, genetic predispo-
sition, and local mucosal environments contribute to disease
severity is not entirely clear. Recent studies in children [6] and
adults [7] support this contention related to severe asthmatic
exacerbations. Understanding the mechanisms that promote
inappropriate immune responses to viral infections may lead
to better therapy. RSV infections are especially detrimental
and have been associated with early and persistent pulmonary
disease, especially in premature infants.
The activation of the innate immune response, including
antigen-presenting DCs, and recruitment of T cells that am-
plify and skew the immune response toward more intense pa-
thology likely contribute to more severe disease and clinical
crisis in asthmatic patients. Whereas various immune responses
to viral infections may have common mechanisms of activa-
tion, RSV appears to promote responses that on their own can
cause severe pulmonary problems [8–10]. Recent evidence
suggests that RSV also has a significant role in elderly patient
populations, as well as in patients with chronic obstructive pul-
monary disease [11]. In addition, the specific mechanism(s) of
immune regulation identified in RSV studies may be relevant
to other viral infections that also must be recognized and
properly cleared to prevent a more pathogenic disease pro-
gression.
A number of studies have shown that RSV infection of DCs
significantly alters the ability of mDCs to express class II and
costimulatory molecules, causes the preferential expression of
IL-10, and impairs the induction of a Th1 response [12–16].
Correspondingly, mucosal mDCs have been shown to preferen-
tially skew immune responses in the lung toward a more
pathogenic Th2 phenotype and lead to severe asthma-like re-
sponses, including increase airway hyper-responsiveness and
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mucus overexpression [17–19]. The migration of DC subsets
to the draining LNs indicates that lung-derived and LN resi-
dent DCs are involved in the presentation of antigen to CD4
and CD8 T cells [20]. The present work examines whether
RSV alters the immune response to a simultaneous allergen
sensitization and secondly, whether RSV-infected DCs played a
role in this process. Our results show that RSV-infected DCs
contribute to this altered immune environment and also that
the DCs need to migrate back to the draining LNs for these
perturbations to occur. We hypothesize that viral infections
provide an inappropriate maturation stimulus that induces the
DC presentation of environmental allergens, thus increasing




Female BALB/c/J and C57BL/6 mice, 6–8 weeks of age, were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA). Animals with spe-
cific genetic deletions of CCR6 and CCR7 were graciously supplied by Pro-
fessor Sergio Lira at Mount Sinai Medical School (New York, NY, USA). All
mice were housed under specific pathogen-free conditions within the ani-
mal care facility at the University of Michigan (Ann Arbor, MI, USA). The
RSV A strain was derived from a clinical isolate at the University of Michi-
gan and was propagated and titered as Line 19 [21, 22]. The mouse-
adapted influenza virus (Strain A/PR/8/34) was purchased from American
Type Culture Collection (Manassas, VA, USA) and was used at a nonlethal
dose following an initial experiment to determine an infectious dose that
was tolerable by all mice (i.e., 100% survival).
Allergen sensitization
In our first set of experiments, the DC-instilled animals were simultane-
ously given a CRA (HollisterSteir, Spokane, WA, USA) sensitization into
the trachea. Fourteen days later, a second administration of allergen
(1 g) was given into the nasal passages, followed by two intratrachea aller-
gen challenges (4 g/mouse) on Days 19 and 21 of the protocol. As our
allergen is a skin-test allergen for clinical use, it has very low or no endo-
toxin and therefore, produces a strong Th2 response without induction of
IFN or IL-17.
In a second protocol designed to determine whether RSV-infected DCs
have a long-term alteration of the pulmonary immune environment, an
intranasal administration of CRA was given 7 days (or 21 days) after the
RSV-infected DC instillation. Subsequently, the animals were given intratra-
chea allergen challenges on Days 13 (or 27 days) and 15 (or 29 days)
post-DC administration. Twenty-four hours after the final allergen chal-
lenge, AHR was assessed, and the lungs and LNs of mice were harvested
for analysis.
Isolation and RSV infection of mouse DCs
BM cells were flushed from the femurs of mice. After RBC lysis, BM cells
were cultured at 1  106 cells/ml in RMPI medium (RPMI 1640, 10% FCS,
1 M Na pyruvate, 2 mM l-glutamine, 100 g/ml streptomycin, 100 U/ml
penicillin) containing 10 ng/ml GM-CSF (R&D Systems, Minneapolis, MN,
USA), and fresh medium was added after 3, 6, and 8 days. On Day 10, DCs
were harvested. These cells represent a mDC population with an intermedi-
ate maturation status, as most cells were CD11c (90%) and also expressed
CD11b (95%). DCs were washed and plated at 2  106/ml and then in-
fected with RSV (0.8106 PFU/ml) or medium alone overnight at 37°C.
CFSE staining of DCs
After RSV infection, 4  106 DCs/ml were stained with the green fluores-
cent dye CFSE (Molecular Probes, Eugene, OR, USA) at a final concentra-
tion of 2.5 M for 5 min at room temperature. After extensive washing,
RSV-infected or control CFSE DCs (0.5106 cells/50 l) were injected
intratracheally on Day 0 after ketamin/xylazin anesthesia. Hereafter, 1, 2,
or 3 days later, lung draining mediastinal LNs were isolated and dispersed
using 0.2% collagenase (Type IV, Sigma-Aldrich, St. Louis, MO, USA) in
RPMI 1640 with 10% FCS at 37°C for 45 min. Single-cell dispersions were
used for flow cytometric analysis.
Flow cytometric analysis of LNs
After blocking nonspecific binding by FcR, cells were stained with anti-
mouse CD11C, CD11b, MHC II, CD80, CD86 or CD40, 7-amino actinomy-
cin D, and Annexin V (all from PharMingen, San Diego, CA, USA; and
eBioscience, San Diego, CA, USA). Cells were analyzed on a Cytomics
FC500 flow cytometer (Beckman-Coulter, Brea, CA, USA).
RSV infection and allergen sensitization (see Fig. 1)
Mice were infected with RSV (1105 PFU/mice) on Day 1 and the
next day, were given a CRA (HollisterStier; 3 g/mouse) sensitization into
the trachea. Fourteen days later, a second administration of allergen (1.5
g/mouse) was given intranasally, followed by two intratrachea allergen
challenges (4 g/mouse) on Days 19 and 21. Twenty-four hours after the
final allergen challenge, AHR was assessed, and the lungs and LNs of mice
were harvested for analysis.
DC transfer and RSV or CRA exposure
After extensive washing, RSV-infected or control DCs (2105 cells/50 l)
were injected intratracheally on Day 0 after ketamin/xylazin anesthesia.
Whereas we cannot rule out completely that the virus was not transferred,
when we examined the lungs at 2–4 days post-DC transfer (a time that is
normally peak virus propagation), we do not find any evidence by PCR of
viral mRNA expression. Thus, the magnitude of any low-level infection
must be very limited.
RSV infection
On Day 7, mice were anesthetized lightly and given RSV (1105 PFU/
mouse) by intratracheal infection, and after 8 additional days, the animals
were analyzed for AHR, cytokine responses, and pathologic changes.
Measurement of airway responses
Airway reactivity in anesthetized mice was measured as described previously
[23]. Briefly, mice were anesthetized with sodium pentobarbital, and the
trachea was cannulated and ventilated using a pump ventilator in a mouse
plethysmograph. After baseline measurements, mice were injected i.v. with
2.5 g methacholine (Sigma-Aldrich), and the peak airway resistance was
recorded.
LN restimulation assays
Single-cell suspensions of lung draining LNs were made by isolating drain-
ing lung LNs, pushing cells through a nylon mesh using a syringe, and
then lysing RBCs. Cells were cultured at a concentration of 6  106
cells/ml in the presence of CRA (2 g/ml) or medium and incubated at
37°C. After 2 days, supernatants were isolated and stored at 80°C until
further analysis. A standardized sandwich ELISA (R&D Systems) or Bio-Plex
(Bio-Rad Laboratories, Hercules, CA, USA) was performed to measure cyto-
kine and chemokine levels in culture supernatants.
Histology
Lungs were maintained in formalin for a further 24 h before being pro-
cessed into paraffin using standard histological techniques. Lung tissue sec-
tions were stained with H&E for analysis of inflammatory cell accumulation
and alcian blue/PAS stain for assessment of mucus production.
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Statistical analysis
Significance was determined using one-way ANOVA with 95% confidence
intervals, followed by a Student Neuman Keuhl’s post-test. With a P value
of 0.05, differences were considered significant.
RESULTS
RSV infection enhances allergen sensitization and
severe pathology associated with mDC accumulation
and responses
A strong correlation in patient populations has been found
between early pulmonary viral infection and subsequent devel-
opment of allergic asthma [24–27]. Although the mechanism
is unknown, it may be that the coincidental exposure of the
viral infection along with an environmental allergen lead to
the most severe disease. To address this latter concept, we ex-
amined whether instilling allergen along with viral infection
would alter the development/sensitization of the allergen re-
sponse. In our studies, the infection of mice with RSV (1105
PFU/mouse) along with allergen sensitization into the airway
clearly elicited a more severe allergic disease after an addi-
tional challenge with the allergen 21 days later (Fig. 1A).
These data include enhanced AHR responses to methacholine
(Fig. 1B), increased potentially pathogenic Th cytokines, IL-4,
IL-5, IL-13, and IL-17 (Fig. 1C), more intense goblet cell devel-
opment in the upper airways (Fig. 1D), and increased expres-
sion of mucus-associated genes gob5 and muc5ac (Fig. 1E). In
contrast, when animals were infected with H1N1 influenza vi-
rus and simultaneously sensitized to allergen using a similar
protocol as RSV, we observed a decrease in allergen-specific
cytokine production and no change in the mucus gene expres-
sion or the histologic appearance (Supplemental Fig. 1).
These data suggest that the RSV, but not influenza, infection
leads to increased sensitization to allergen and caused an in-
tensified local skewing response [28]. Thus, not all viral infec-
tions can promote an enhanced allergic airway response.
To determine the contribution of the mDC to the intensi-
fied response, BMDCs were infected with RSV in vitro (MOI,
1.0). This procedure addressed the effects of the RSV infec-
tion of airways, as DCs do not propagate RSV but did sensitize
animals to the responses as described above. To address virus
propagation from DCs that were transferred, we examined a
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Figure 1. RSV enhances and exacerbates CRA-induced disease pathology. As
indicated in the time line (A), when RSV is given into the airway of naïve
mice 1 day prior to allergen, followed by a 21-day sensitization protocol, there
is an increased clinical disease, as represented by methacholine-induced AHR
after a final allergen challenge (B). Allergen-restimulated lung draining LNs
demonstrated enhanced Th2 cytokines and IL-17 in animals given RSV along
with allergen (C). The overproduction of mucus, as depicted histologically
(D) and by mucus-associated gene expression profiles (E), was also increased
significantly by the presence of a RSV infection at the time of initial allergen
sensitization. Data represent mean  se from five mice/group. *P  0.05.
Jang et al. RSV-infected DCs accelerate allergen sensitization
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time-course analysis (24–72 h postinfection) of RSV-infected
DCs in vitro and found no virus propagation from DCs by
plaque analysis at any time-point based on continuous decreas-
ing levels of plaqued virus (0.04% of input at 24 h, 0.004% by
48 h, and none by 72 h; Supplemental Fig. 2A). However,
when we examined RSV protein mRNA expression in lungs of
mice at 2 days post-DC transfers, we found some evidence of
RSV infection based on qPCR results, although at a barely de-
tectable level compared with a live virus infection (Supplemen-
tal Fig. 2B). The data in Fig. 2 demonstrate that RSV-infected
DC leads to an exacerbation of the allergic response with a
significantly increased AHR response compared with controls
(Fig. 2A). Additionally, IL-13, IL-17, and IFN were increased
significantly, and mucus gene expression was also increased
compared with controls (Fig. 2B and C). Interestingly, it was
only in the presence of RSV-infected DCs that the allergen-
rechallenged LN cells produced IL-17 (Fig. 2B). Moreover,
simply delivering additional DCs into the airway at the time
of allergen sensitization enhanced the Th2 cytokine sensiti-
zation; however, the activation of those DCs with RSV prior
to instillation induced an even more intense and broader
profile response (Fig. 2B). Thus, the DCs enhance the
pathologic response, not only by promoting allergen sensiti-
zation but also by inducing potentially pathogenic IL-17.
Characterization of the in vitro-infected DC demonstrated
that RSV up-regulated CD80, CD86, and CD40 (Supplemen-
tal Fig. 2C) but did not induce apoptotic or necrotic cell
death (Supplemental Fig. 2D).
To further address whether the recruitment and accumula-
tion of mDC subsets are necessary for the development of the
RSV-induced enhanced allergic responses described above,
CCR6/ mice were used. Studies from several laboratories,
including our own, have demonstrated that CCR6/ ani-
mals have a defect in mDC accumulation, but not T cells,
within the lungs of RSV-infected or allergen-sensitized animals
[29–35]. The infection of WT and CCR6/ mice with RSV,
along with allergen sensitization, was repeated as described
above in Fig. 1A. As published previously, we also observed
decreases in CD11b/CD11c DC accumulation but no differ-
ence in T cell populations that accumulated in the sensitized
and challenged mice (data not shown). Mice rechallenged at
Day 21 demonstrated a striking reduction of RSV-induced ex-
acerbation of AHR in the CCR6/ mice compared with WT
control mice (Fig. 3A). Also, the CCR6/ animals histologi-
cally displayed a significant reduction in overall inflammation
and reduction in mucus production, and this was supported by
quantification of mucus gene expression (Fig. 3B). Finally,
when cytokine responses were examined, there was a decrease
in the expression of Th2 cytokines in the RSV-exacerbated re-
sponses (Fig. 3C). However, whereas IL-17 was up-regulated by
the RSV exposure, it was not reduced in the CCR6/ mice
(data not shown).
RSV infection predisposes animals to more severe
pulmonary responses via DC activation and LN localization
Previous data have indicated that the severity of RSV-induced
pathology can be associated with the presence of defined DC
































































































Figure 2. RSV-infected DC instilled into the airways of mice can re-
place a live RSV infection for exacerbation of allergen-induced
responses. After an overnight infection, the washed DCs were trans-
ferred into the lungs of naïve mice by intratracheal administration,
along with CRA. With the use of the same timeline as in Fig. 1, mice
were challenged with CRA by intranasal (Day 14) and intratrachea de-
livery (Days 19 and 21), and 24 h after final allergen exposure, there-
sponses were assessed. The RSV-infected DCs induced a significant in-
crease in AHR (A) compared with results with no DC  allergen or
(continued) uninfected DC  allergen. When lung draining LN cells
were restimulated in vitro with allergen at the end of the in vivo re-
sponses, changes in secreted cytokines were observed in the RSV-DC-
treated mice compared with the other groups, as assessed in 48-h cul-
ture supernatants by Bio-Plex analysis (B). There was also a significant
increase in mucus-associated genes in whole lung qPCR (C). Data rep-
resent mean  se from five mice/group. *P  0.05.
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mucosal (lung) mDCs were shown to be responsible for skew-
ing the immune responses toward a modified Th cell response
that becomes more pathogenic [15, 17–19, 40]. Thus, we ex-
amined whether RSV-infected DCs also skewed a RSV infection
challenge, as observed above with allergen. To examine this
aspect specifically, BMDCs (CD11c/CD11b) were cultured
overnight, with or without RSV (MOI of 1), in vitro to allow
infection, subsequently washed free of excess virus, and in-
stilled into the trachea of naïve mice (2105 DC/mouse). Af-
ter 7 days, the mice were infected with RSV, and the immune
response was assayed to determine if the infected BMDCs al-
tered the immune environment. The data in Fig. 4A demon-
strate that those animals that received RSV-infected BMDCs
had an enhanced IL-4, IL-5, and IL-13 Th2-induced immune
response, whereas IL-17 and IFN- production were down-reg-
ulated. This was accompanied by increases in mucus overex-
pression and airway pathology (Fig. 4B and C). Our studies
also observed a decrease in RSV-specific mRNA, as might be
expected with a local sensitization (data not shown) [41].
Thus, this response suggests that exogenously added DCs alter
immune responses to the virus and resulted in increased pa-
thology via Th2 cytokine overproduction in agreement with
other studies [42–45].
We next determined whether RSV infection enhances migra-
tion of DCs to the LN. The data in Fig. 5A depict flow cytom-
etry of the draining LNs from the instilled mice at different
time-points, indicating that RSV-infected DCs traffic better to

















































































































































Figure 3. Attenuation of RSV exacerbated allergen sensitization in CCR6/ mice. With the use of the sensitization protocol established in Fig. 1,
WT or CCR6/ [knockout (KO)] was sensitized to CRA, with or without RSV infection. Mice were challenged with CRA intranasally (Day 14)
and intratrachelly (Days 19 and 21), and the responses were assessed. Twenty-four hours after final allergen exposure, mice were examined for
methacholine-induced AHR (A). Differences in mucus hypersecretion in RSV-enhanced allergic disease were depicted by examining histology and
mucus-associated genes muc5ac and gob5 by qPCR of lung mRNA (B). There was also a significant increase in Th2 genes, IL-4 and IL-13, in lung
qPCR (C). Data represent mean  se from five mice/group. *P  0.05.
Jang et al. RSV-infected DCs accelerate allergen sensitization
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and enhances their migration into the draining LNs of mice,
potentially facilitating sensitization of the immune response.
Our next series of studies was set up to determine whether
the trafficking of the RSV-infected DCs to the LN was required
for the altered responses, as previous studies have demon-
strated that lung as well as LN resident DCs are involved in
RSV-specific CD4 and CD8 T cell activation [20]. To address
this question, studies used a similar system as described above
with BMDCs from WT or CCR7/ mice. To verify that the
CCR7/ DCs were impaired in their ability to traffic to
draining LNs, as reported [46], the nodes were harvested at
24 h and 48 h postinstillation of CFSE-labeled, RSV-infected
DCs. The data in Fig. 5B confirmed that DCs from CCR7/
animals do not traffic efficiently to the LNs after RSV infec-
tion. Seven days after the instillation of RSV-infected DC into
the lungs of naïve mice, the animals were infected with RSV.
Following 8 days of infection, the draining LNs were har-
vested, and the isolated cells rechallenged in vitro with a RSV
infection. The resulting response indicated that when
CCR7/ DCs were used for airway sensitization, there was a
significant reduction of Th2 cytokines with no change in IL-17
expression (Fig. 5C). Thus, the exacerbated immune response
appears to be, at least partially, dependent on LN accumula-
tion of the instilled, RSV-infected DCs and also enhances the
pathogenic response to subsequent challenges. These re-
sponses should help identify the locational requirements for
altering the immune responses during respiratory viral infec-
tions that may enhance allergen responses.
RSV-infected DC enhancement of allergic responses
does not need to be simultaneous
We next examined whether the RSV-infected DCs have a long-
term effect on allergen sensitization. Isolated DCs were in-
fected with RSV and instilled into the airway as above. After 7
days of sensitization, the animals were given an allergen sensi-
tization into the airway via intranasal delivery. Following an
additional 6 days, the animals were again challenged twice
with intratracheal allergen, 48 h apart. This suboptimal aller-
gen-sensitization process led to increases in AHR responses
(Fig. 6A) and increases in Th2 cytokines IL-4, IL-5, and IL-13
(Fig. 6B), with no allergen-specific increase in IL-17 detected
(data not shown). Histologic studies of PAS-stained lungs
showed that although the mice receiving DCs alone displayed
significant inflammatory cell infiltration, a significantly more
mucogenic response was observed in animals given RSV-in-
fected DCs prior to the allergen (Fig. 6C). Furthermore, when
we waited for 21 days after RSV-infected DC instillation, prior
to the allergen sensitization, the Th2 cytokine response contin-
ued to be enhanced by the RSV-DC transfer, with increased
pathology characterized by mucus overproduction (Supple-
mental Fig. 3). Thus, these data indicate that RSV-infected
DCs accelerated the allergen-sensitization process and caused
Th2 cytokine skewing, leading to more severe disease, even
when given up to 21 days prior to allergen exposure.
DISCUSSION
In these studies, we have begun to address several important
mechanistic questions, including: are there detrimental effects
of an antiviral immune response within the pulmonary envi-
ronment that lead to a more pathogenic response to noninfec-
tious (allergen) stimuli? Can innate immune cells (DCs) dic-
tate the nature of a subsequent immune response? Although
the present studies have only begun to address these issues,
the data do correlate with clinical observations, suggesting that
early viral infections can lead to long-term effects that alter
subsequent immune responses [26, 27, 47, 48]. The role of
RSV for development of childhood pulmonary disease has
been epidemiologically controversial [9, 25, 47, 49–54], and
several reports have begun to address the role of RSV in
model allergen systems [55–61]. In fact, a recent publication
has indicated that RSV can break an induced, antigen-specific
tolerance response by altering regulatory T cell function [62].
Although RSV itself appears to promote a dysregulated innate
immune response via specific NS proteins (NS1 and NS2)
[63–66], it may be that the virus infection is a stimulus for en-



























Figure 4. Airway sensitization of mice with RSV-infected DCs elicited a Th2-skewed immune response upon a RSV infection challenge. RSV-in-
fected BMDC (2105/mouse) were instilled into the airways of naïve mice and infected with live RSV (1105 PFU/mouse), 7 days after BMDC
instillation. Supernatants from RSV-restimulated lung draining LN cells were analyzed for cytokines by Bio-Plex (A). Lungs were taken 8 days after
the additional RSV infection (15 days later, the DC-RSV instillation) and were stained with PAS (B) and assessed by qPCR for mucus genes (C).
Data represent mean  se from five mice/group. *P  0.05.
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hancing sensitization and leads to the altered immune re-
sponses. This was manifested in our studies using the DC sen-
sitization model, where the active infection was replaced with
RSV-infected DCs that propagate undetectable levels of active
virions. In contrast, influenza infection did not induce a simi-
lar state of exacerbated disease and in fact, inhibited the skew-
ing of allergen-specific responses. This latter change may be
associated with differences in key mediators that are induced
by the two viruses, such as type I IFN, which is highly induce
by influenza [67] but inhibited by RSV NS1 and NS2 proteins
[63, 65, 68]. With the use of DCs from CCR7/ mice, stud-
ies established that migration into the LN was one necessary
step for the altered immune response to a subsequent RSV
infection. In patient populations, especially immune “inexperi-
enced” infants, early viral infection may aid in the improper
sensitization of individuals to environmental allergens. This
effect, along with a genetic predisposition to an altered pulmo-
nary environment, could lead to an enhanced pathologic re-
sponse within the lung. The results, showing that the infected
DC-induced immune deviation lasted 1 week and as long as 21
days, suggest that these cells are primarily involved in the pro-
cess, either directly via APC function or indirectly by mediator
release, such as IL-10 [69, 70]. Although the use of BMDCs is
not entirely physiologic and the relevance to lung DC unclear,
the studies help to identify a potential cellular mechanism of
how RSV can alter an immune environment. Future studies
will be needed to resolve these issues and to test exactly how
long this effect persists.
One of the primary implications of our data is the relative
























































































































Figure 5. BMDC from CCR6/
mice do not migrate to draining LNs
and fail to sensitize mice for an exac-
erbated RSV infection response. BMDCs
were cultured overnight, with or with-
out RSV, and stained with CFSE. After
an injection of DCs into mice by in-
tratrachea injection, lung draining
LNs were isolated at different time-
points, and single-cell dispersions
were used for flow cytometry analysis
(A). Left panel is flow cytometry plot
at 24 h time-point. R1 represents
CD11c CFSE-positive cells. Similar
results were observed at 48-h and 72-h
later time-points (right panel). WT
and CCR7/ BMDCs were infected
with RSV and were stained with CFSE.
Lung draining LNs were isolated after
24 h and 48 h and performed flow
cytometric analysis (B). Supernatants
from RSV-restimulated LN cells were
analyzed for cytokines by Bio-Plex
(C). Data represent mean  se from
five mice/group. *P  0.05.
Jang et al. RSV-infected DCs accelerate allergen sensitization
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that extends its influence on a noninfectious allergen re-
sponse. This raises the possibility that specific viral infections
preferentially alter the immune environment as a result of a
modified immune response. As mentioned above, this may be
a result of specific viral proteins, such as the NS proteins of
RSV that can inhibit key innate cytokines, and/or the entry of
RSV via a nonendosomic route [71]. This latter concept is in-
triguing, as a primary mechanism for type I IFN production
during RSV infection in epithelial cells is via the cytoplasmic
sensor RIG-I that recognizes dsRNA [72, 73]. Recent studies
have shown that the NS2 protein of RSV antagonizes IFN-
production induced by RIG-I [74]. Other studies have clearly
demonstrated a skewed pathogenic environment in the ab-
sence of STAT1, an essential downstream signaling molecule
for type I IFN expression [75–78]. Thus, DC activation and
mediator release are affected directly by RSV infection. Subse-
quently, TLRs found in the endosome are also activated and
contribute to the innate immune response during RSV infec-
tion [79–81]. Other studies have suggested that RSV G pro-
tein can inhibit TLR-induced activation [82]. Interestingly,
when the RIG-I pathway and MyD88-dependent TLR pathways
were blocked in mitochondrial antiviral-signaling protein/
MyD88 double-knockout mice, no alteration in cytotoxic T cell
development and viral clearance was observed [83]. Likewise,
the use of any one of several knockout mice deficient in TLR
or MyD88 signaling did not alter viral clearance; however, sig-
nificantly altered immune responses and increased pathogene-
sis during RSV infection were observed [79, 80, 84–86]. Thus,
there may be multiple mechanisms for immune response alter-
ation during RSV infection that can influence the direction
and/or quality of the immune responses and therefore, the
pathologic outcome.
The cytokine profile induced with a primary RSV-infected
DC sensitization into the airway was a skewed Th2 response
with decreases in IFN and IL-17 upon a RSV infection. A dif-
ferent profile was recognized when mice were infected with
RSV coincident with allergen sensitization with an allergen-
specific increase in Th2 and Th17 cytokines. Although one
could explain these responses by the ability of RSV to cause
enhanced DC migration to the LNs (as demonstrated with the
CCR7/ DC studies), the ability to achieve enhanced aller-
gen-induced Th2 responses, 1–3 weeks after RSV-DC instilla-
tion into the airway, is more difficult to explain. Previous stud-
ies have clearly suggested that pulmonary mDC populations
have a preferential ability to skew the local immune responses
toward a Th2-type immune environment [17–19, 87]. How-
ever, as described in a recent study by Guerrero-Plata et al.
[88], pDCs also appear to be altered upon RSV infection. This
latter effect may be important, as pDCs have a pivotal role in
establishing an appropriate anti-RSV response and are neces-
sary for maintaining a toleragenic immune environment
against locally administered antigens/allergens [36, 38, 39].
Recent evidence has suggested that the NS proteins from RSV
also suppress the maturation of DCs, including costimulatory
proteins CD80, CD83, and CD86, and are associated with pre-
viously described reductions in type I IFN production [16].
Thus, the altered immune environment that was characterized
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Figure 6. RSV-infected BMDC-
induced allergen exacerbation is
long-lived and does not need to be
simultaneous. The BMDCs were
infected with RSV (MOI1.0) and
instilled into naïve Balb/c mice.
After 1 week, the mice were ex-
posed to CRA (1 g/mouse) by
intranasal instillation with repeated
instillations, 6 and 8 days later
(Days 13 and 15 of the protocol).
Twenty-four hours after final aller-
gen exposure (Day 16), the ani-
mals were assessed for AHR (A) by
methacholine challenge. Cont,
Control. Draining LNs were pre-
pared to single-cell suspension and
restimulated with allergen (2 g/
ml) and 48-h culture supernatant
assessed for cytokines by Bio-Plex
analysis (B). Formalin-preserved lung
tissue (left lobe) was assessed for mu-
cus and goblet cell hypertrophy by
PAS staining of histology sections (C).
Data represent mean  se from five
mice/group. *P  0.05.
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altered DC maturation. Although our studies have focused on
using a BMDC that best resembles a monocyte-derived DC sub-
set (CD11b/CD11c), there are other important subsets in
the lung, especially the CD103 subset that appears to be rele-
vant in RSV infection [20]. The CD103 subset is migratory
and has been suggested to better promote an antiviral Th1-
type cytotoxic T cell response as a result of its ability to cross-
present antigens [20, 89–93]. In contrast, a more recent study
indicated that pulmonary CD103 DCs were better able than
CD11b DCs at promoting Th2 cytokine responses when an
inert antigen (OVA) was used [94]. Thus, offsetting the bal-
ance of the subset ratios by adding a CD11b/CD11c DCs
may represent a highly inflamed environment that promotes
the recruitment of more “inflammatory”-type DCs that migrate
into the lung and initiate pathologic responses. In our studies,
when we examined the CFSE trafficking of infected DCs into
the LN, we had no evidence that the CD103 cells were in-
volved in the process, but we cannot rule out their contribu-
tion to the process. However, the use of CCR6/ mice,
which have altered inflammatory CD11b/CD11c DC accumula-
tion after RSV and allergen exposures [29, 34, 35], further
supports the concept that altering DC subset ratios can affect
the outcome of the pulmonary response. Interestingly, our
studies observed no alteration in IL-17 production in
CCR6/ or CCR7/ studies in the presence of RSV, but
we have not pursued this further at this time.
The data presented in these studies suggest that alteration
of the pulmonary immune environment by RSV infection may
have an underlying effect on the progression of disease pathol-
ogy. Although several inter-related mechanisms may be in-
duced, these studies suggest that RSV infections may predis-
pose the host to an altered and modified disease phenotype
through activation of DC subsets that may allow immune re-
sponses to allergens to be altered. Future studies will explore
the nature of the RSV-mediated DC alteration.
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